BIOGEN INC. Payments of Financing Costs
BIOGEN INC. (BIIB) reported Payments of Financing Costs of $24.40 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-10-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2021-10-20
- BIOGEN INC. payments of financing costs for the quarter ending 2021-09-30 was $0.00.
- BIOGEN INC. payments of financing costs for the quarter ending 2021-06-30 was $0.00.
- BIOGEN INC. payments of financing costs for the quarter ending 2021-03-31 was $24.40M.
- BIOGEN INC. payments of financing costs for the quarter ending 2020-09-30 was $0.00.
- BIOGEN INC. payments of financing costs for fiscal 2015 was $47.50M.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month | Payments of Financing Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | $0.00 derived: sum of 2 quarters · filed 2021-10-20 | $24.40M 10-Q · filed 2021-10-20 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22 | $24.40M 10-Q · filed 2021-07-22 | |||
| 2021-03-31 | $24.40M 10-Q · filed 2021-04-22 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $24.40M 10-Q · filed 2020-10-21 | |||
| 2020-06-30 | $24.40M 10-Q · filed 2020-07-22 | ||||
| 2015-12-31 | $47.50M 10-K · filed 2020-02-06 | $52.00M 10-K · filed 2017-02-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |